Thomson Horstmann & Bryant Inc. acquired a new position in shares of CryoLife, Inc. (NYSE:CRY) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 93,925 shares of the medical equipment provider’s stock, valued at approximately $1,873,000. Thomson Horstmann & Bryant Inc. owned approximately 0.28% of CryoLife at the end of the most recent reporting period.
A number of other institutional investors have also recently bought and sold shares of CRY. Louisiana State Employees Retirement System raised its position in CryoLife by 0.9% in the second quarter. Louisiana State Employees Retirement System now owns 11,100 shares of the medical equipment provider’s stock worth $221,000 after buying an additional 100 shares in the last quarter. Municipal Employees Retirement System of Michigan raised its position in CryoLife by 3.2% in the first quarter. Municipal Employees Retirement System of Michigan now owns 6,150 shares of the medical equipment provider’s stock worth $102,000 after buying an additional 190 shares in the last quarter. Arizona State Retirement System raised its position in CryoLife by 1.4% in the first quarter. Arizona State Retirement System now owns 14,054 shares of the medical equipment provider’s stock worth $234,000 after buying an additional 200 shares in the last quarter. Creative Planning boosted its stake in shares of CryoLife by 3.0% in the second quarter. Creative Planning now owns 6,806 shares of the medical equipment provider’s stock worth $136,000 after buying an additional 200 shares during the last quarter. Finally, Mason Street Advisors LLC boosted its stake in shares of CryoLife by 7.4% in the first quarter. Mason Street Advisors LLC now owns 6,324 shares of the medical equipment provider’s stock worth $105,000 after buying an additional 438 shares during the last quarter. 68.13% of the stock is owned by institutional investors.
CryoLife, Inc. (CRY) traded up 0.27% on Friday, hitting $18.40. 75,296 shares of the stock traded hands. The firm’s 50 day moving average is $19.30 and its 200 day moving average is $17.96. The stock has a market cap of $615.41 million, a price-to-earnings ratio of 55.76 and a beta of 0.97. CryoLife, Inc. has a 52 week low of $14.03 and a 52 week high of $20.30.
CryoLife (NYSE:CRY) last issued its quarterly earnings results on Monday, July 24th. The medical equipment provider reported $0.12 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.10 by $0.02. CryoLife had a net margin of 6.16% and a return on equity of 7.41%. The company had revenue of $47.80 million for the quarter, compared to the consensus estimate of $47.02 million. During the same period in the previous year, the firm earned $0.13 EPS. The firm’s quarterly revenue was up 1.5% on a year-over-year basis. Equities analysts anticipate that CryoLife, Inc. will post $0.43 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: This article was posted by BNB Daily and is owned by of BNB Daily. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright law. The correct version of this article can be viewed at https://www.baseball-news-blog.com/2017/08/13/thomson-horstmann-bryant-inc-takes-position-in-cryolife-inc-cry-updated-updated.html.
CRY has been the subject of a number of research reports. Zacks Investment Research upgraded shares of CryoLife from a “hold” rating to a “buy” rating and set a $21.00 target price for the company in a report on Thursday, June 8th. BidaskClub lowered shares of CryoLife from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Finally, Northland Securities reissued a “buy” rating and set a $23.50 target price on shares of CryoLife in a research note on Friday, April 28th. Two investment analysts have rated the stock with a sell rating and three have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $22.00.
In other news, VP Amy Horton sold 9,577 shares of the company’s stock in a transaction dated Tuesday, June 27th. The stock was sold at an average price of $20.00, for a total transaction of $191,540.00. Following the sale, the vice president now directly owns 112,282 shares in the company, valued at $2,245,640. The sale was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 6.00% of the company’s stock.
CryoLife Company Profile
CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.
Receive News & Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related companies with MarketBeat.com's FREE daily email newsletter.